Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:21 AM
Ignite Modification Date:
2025-12-25 @ 3:21 AM
NCT ID:
NCT05064605
Eligibility Criteria:
Inclusion Criteria:
* Patient over 18 years of age
* Diagnosis of PCA made according to the criteria of Denning et al. Eur Respir J. 2016
* Previously initiated or newly initiated azole antifungal therapy for chronic lung disease complicated by CPA.
* Informed patients who did not object to the use of their data.
Exclusion Criteria:
* Pregnant woman
* Co-medication affecting the pharmacokinetics of antifungal agents:
Enzyme inducing therapy (rifampin, rifabutin, phenytoin, phenobarbital, efavirenz, nevirapine, etravirine, ritonavir in the case of voriconazole) Drugs that may inhibit the metabolism of antifungal drugs (ritonavir and cobicistat for itraconazole and isavuconazole)
* Patients under guardianship/guardianship
* Patients without social security coverage
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05064605
Study Brief:
Protocol Section:
NCT05064605